Heron Therapeutics Announces Prior Approval Supplement Submission To FDA For ZYNRELEF VAN
Portfolio Pulse from Benzinga Newsdesk
Heron Therapeutics has submitted a Prior Approval Supplement to the FDA for ZYNRELEF VAN, a move that could potentially enhance the product's marketability and usage.
May 29, 2024 | 12:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Heron Therapeutics has submitted a Prior Approval Supplement to the FDA for ZYNRELEF VAN. This regulatory step could enhance the product's marketability and usage, potentially leading to increased revenues.
The submission of a Prior Approval Supplement to the FDA is a significant regulatory step that could lead to enhanced marketability and usage of ZYNRELEF VAN. This could result in increased revenues for Heron Therapeutics, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100